MarketVIEW Zoonotic & RNA Virus Vaccines  ·  July 2020 edition

Rift Valley Fever
Vaccines Forecast

Rift Valley Fever has quietly killed thousands across Sub-Saharan Africa and the Arabian Peninsula since the 1990s, and in 2025 it returned to Senegal in one of its most severe forms since 1987. That same year, Oxford and CEPI's ChAdOx1 candidate entered Phase II trials in an outbreak-prone corner of Kenya, and CEPI backed the field's first mRNA candidate. This is the independent commercial assessment of what a workable human vaccine could be worth, drawing on VacZine Analytics' long-standing, independent authority in RNA virus and zoonotic disease vaccine markets.

Severe 2025 Senegal Outbreak ChAdOx1 Now Phase II (Kenya) Afrigen mRNA Candidate CEPI-Backed 34 Countries Modelled to 2040
Product catalogue
VAMV085
July 2020 edition

Format
PDF (>120 slides) + Excel
Coverage
34 countries (human vaccine)
Vaccines assessed
ChAdOx1 RVF, Afrigen mRNA
Forecast horizon
To 2040
Approach
Scenario-based, TPP-driven
Base edition
July 2020
Availability
Syndicated / bespoke
500K+
RVF cases estimated 1997 to 2010,
with over 2,000 deaths
554
Confirmed human cases in the 2025
Senegal outbreak (31 deaths)
34
Countries modelled for a
human RVF vaccine (some rolled up)
2025
Year ChAdOx1 entered Phase II
and Afrigen's mRNA candidate was funded
Disease background

Why Rift Valley Fever remains a CEPI priority pathogen

Rift Valley Fever is a textbook example of a neglected zoonotic threat: intermittently devastating, geographically expanding, and without any vaccine licensed for large-scale human use. Understanding both its historical burden and the events of 2025 is central to understanding what a workable human vaccine could be worth.

Outbreak surveillance & 2025/2026 pipeline data

Pathogen overview - Rift Valley Fever Virus (RVFV)

Rift Valley Fever (RVF) is an acute zoonotic disease affecting domestic and wild ruminants that can also cause moderate to severe illness in humans. It is caused by Rift Valley Fever Virus (RVFV), a negative single-stranded RNA arbovirus of the genus Phlebovirus. The main route of human infection is contact with tissues or bodily fluids of infected livestock, or consumption of raw milk; mosquitoes can also transmit the virus to both animals and humans. To date, no human-to-human transmission has been documented.

RVF has mainly affected Sub-Saharan Africa, with major outbreaks in Kenya (1997 to 1998), Somalia and Tanzania, and more recent outbreaks in Saudi Arabia and Yemen (2000 to 2001). Between 1997 and 2010, an estimated more than 500,000 cases of RVF occurred, with over 2,000 reported deaths. A key concern is that further outbreaks could occur in non-endemic areas where competent mosquito vectors already exist. RVF can also cause significant economic damage and contribute to famine in regions reliant on livestock rearing and food trading.

That concern was realised in 2025. Senegal declared an RVF outbreak in September 2025, its first to cause human deaths since 1987; by mid-December, 554 confirmed human cases and 31 deaths had been reported, spreading from the Saint-Louis region into Matam and Louga. Genomic analysis confirmed lineage H, a strain previously associated with severe outbreaks in Mauritania, South Africa and Namibia, and heavy rainfall and flooding are believed to have amplified mosquito breeding and outbreak severity. This followed a comparatively mild 2024, in which just 12 cases across Mauritania, Kenya, Senegal and Uganda produced no deaths, underscoring how unpredictable RVF's year-to-year burden can be.

RVFV has been designated a priority pathogen by both the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organisation. An inactivated vaccine exists for human use under a Special Immunization Program, but its profile is not suitable, or licensed, for large-scale deployment. That gap is now closing on two fronts. Oxford's ChAdOx1 RVF candidate, built on the same viral vector platform that underpinned the Oxford-AstraZeneca COVID-19 vaccine, showed a favourable safety and immunogenicity profile in Phase 1 trials in the UK and Uganda, and in July 2025 began a CEPI-funded Phase II trial in Kilifi, Kenya, enrolling 240 healthy adults, the most advanced RVF vaccine study yet run in an outbreak-prone region. In January 2025, CEPI committed 6.2 million US dollars to South Africa's Afrigen Biologics, working with the International Vaccine Institute, to develop the field's first mRNA-based RVF vaccine candidate, progressing it from preclinical development into Phase 1 human testing.

2026 554 cases / 31 deaths in the 2025 Senegal outbreak  |  lineage H strain confirmed  |  ChAdOx1 now in Phase II (Kenya)  |  Afrigen's mRNA candidate CEPI-funded
Product & competitor landscape

A viral vector candidate now in Phase II, and an mRNA candidate right behind it

Human RVF vaccine development has historically trailed the animal-health field, constrained by the disease's unpredictable, outbreak-driven epidemiology. That has changed markedly since 2025, with two CEPI-backed candidates now advancing through clinical and preclinical development on two different platforms.

  • Oxford / CEPIPhase II (2025)
    ChAdOx1 RVF Viral vector
    Uses the same chimpanzee adenovirus vector platform (ChAdOx1) that underpinned the Oxford-AstraZeneca COVID-19 vaccine. Phase 1 trials in the UK and Uganda showed a favourable safety and immunogenicity profile. In July 2025, a CEPI-funded Phase II trial began in Kilifi, Kenya, enrolling 240 healthy adults, led by the KEMRI-Wellcome Trust Research Programme and Oxford University, the most advanced RVF vaccine study yet conducted in an outbreak-prone region.
  • Afrigen BiologicsPreclinical to Phase 1
    mRNA candidate First mRNA approach
    CEPI's fourth investment in RVF vaccine development, and its first in an mRNA-based candidate. Announced January 2025 with a 6.2 million US dollar grant, developed in partnership with the International Vaccine Institute, progressing from preclinical development into Phase 1 human testing in South Africa or another outbreak-affected country.
  • Special Immunization ProgramExisting, limited use
    Inactivated vaccine
    An existing inactivated vaccine is available for human use under restricted access programmes, but its profile, requiring multiple doses and with limited manufacturing scale, is not suitable or licensed for large-scale deployment.
  • Veterinary sectorAdjacent market
    Livestock vaccines
    Live-attenuated and inactivated veterinary vaccines are used to protect livestock and reduce spillover risk, forming an important adjacent market and a key input into human exposure-risk modelling.
Inflection point
2025

2025 delivered both the proof of concern and the first credible response: Senegal's most severe RVF outbreak since 1987 struck the same year that ChAdOx1 entered Phase II testing in neighbouring Kenya and CEPI backed the field's first mRNA candidate. With competent mosquito vectors present well beyond current endemic zones, the case for a deployable human vaccine has rarely been clearer. The VacZine Analytics model quantifies the commercial opportunity under multiple outbreak-frequency and pipeline-progression scenarios.

Scope of analysis

Six analytical layers - one commercial picture

The MarketVIEW Rift Valley Fever analysis spans disease burden, target population rationale, the post-2025 competitor landscape and scenario-based value forecasting across 34 countries to 2040, public and private sector.

At-risk population forecast to 2040

Bottom-up modelling across 34 countries (some rolled up), covering at-risk populations and identified target segments in public and private sectors.

Competitor & pipeline review

Oxford/CEPI's ChAdOx1 candidate now in Phase II, Afrigen's CEPI-backed mRNA programme, and the existing inactivated vaccine's limitations.

Platform & vaccinology assessment

Viral vector versus mRNA versus inactivated approaches, and their respective manufacturability and deployment implications for outbreak response.

Scenario-based value forecasts

Base, upside and conservative value and volume scenarios to 2040, reflecting outbreak-frequency and pipeline-progression assumptions.

Disease burden & outbreak surveillance

Historical 1997 to 2010 burden data alongside the 2024 and 2025 outbreak record, including the lineage H strain behind Senegal's 2025 outbreak.

Target product profile discussion

Hypothetical vaccine target product profiles (TPPs), target population rationale, and outbreak-response stockpile considerations.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the target-population and scenario framework. Full value/volume outputs, pricing assumptions and country-level data are in the licensed model.

Target populationGeographyMarket typeVaccine profileValue scenario
Rural / livestock-dependent populationsEndemic Sub-Saharan AfricaPublic programmeRoutine / preventiveModelled
Occupational exposure (farmers, vets, abattoir workers)34-country modelPublic + privateTargeted / at-riskModelled
Outbreak-response stockpileNon-endemic at-risk areasPublic procurementReactive / stockpiledModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - base34-country modelAllAll profiles$███m
Full model in the licensed workbook
34 countries · to 2040 · target group · pricing detail
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and an interactive forecast model, built for decision-makers who need the full picture on the Rift Valley Fever vaccine opportunity.

  • Executive presentation (>120 slides, PDF) - disease background, epidemiology, outbreak history through 2025, competitor pipeline and full commercial assessment with supporting narrative and references
  • MS-Excel forecast workbook - value and volume outputs across a 34-country model (some rolled up), public and private sector, to 2040
  • Scenario-based commercial forecasts - base, upside and conservative cases reflecting outbreak-frequency and pipeline-progression assumptions
  • Competitor intelligence - ChAdOx1 RVF (Oxford/CEPI), Afrigen's mRNA candidate, and the existing inactivated vaccine's deployment limitations
  • Updated epidemiology & outbreak module - historical 1997 to 2010 burden data plus the 2024 and 2025 outbreak record, including lineage H genomic findings
  • Target product profile (TPP) discussion - hypothetical vaccine profiles, target population rationale, pricing and clinical development feasibility
Target audience

Built for organisations weighing the RVF opportunity

Most valuable to teams evaluating the Rift Valley Fever vaccine market against their own pipeline, BD ambitions or investment thesis, particularly in light of the 2025 Senegal outbreak and the two CEPI-backed candidates now advancing behind it.

Vaccine developers

Positioning, commercial feasibility and target-population prioritisation for RVF candidates at any stage.

Corporate strategy & BD

Validate market size and structure now that two CEPI-backed candidates are advancing through clinical and preclinical development.

Investors & analysts

Independent assessment of market size and pipeline risk for due diligence on RVF and adjacent zoonotic/RNA virus vaccine assets.

Public health & pandemic preparedness

Demand modelling for outbreak-response stockpiling and CEPI-aligned epidemic preparedness programmes.

Researchers & academia

Comprehensive epidemiology and vaccine landscape for grant and translational planning, including outbreak genomics.

Market access & policy

Pricing benchmarks and access-pathway assumptions across public procurement and stockpile-driven channels.

About this analysis · VAMV085

VacZine Analytics has tracked RNA virus and zoonotic disease vaccine markets since our earliest editions, positioning us to reassess the Rift Valley Fever opportunity the moment the outbreak record and pipeline both shifted. This analysis combines a rigorous epidemiological and outbreak-surveillance review with an independently constructed commercial model spanning a 34-country geography that most forecasts model only in aggregate. Few groups have followed this market as closely or for as long, and that recognised, independent expertise underpins everything in the analysis, which has been well received by clients across the field.

This July 2020 edition has been updated to incorporate the severe 2025 Senegal outbreak and lineage H genomic findings, the July 2025 start of ChAdOx1's Phase II trial in Kenya, and CEPI's January 2025 funding of Afrigen's mRNA candidate. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV085 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Rift Valley Fever analysis, a briefing call is included on request.